109 related articles for article (PubMed ID: 9789740)
41. Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies.
Bartonová V; Král V; Sieglová I; Brynda J; Fábry M; Horejsí M; Kozísek M; Sasková KG; Konvalinka J; Sedlácek J; Rezácová P
Antiviral Res; 2008 Jun; 78(3):275-7. PubMed ID: 18329737
[TBL] [Abstract][Full Text] [Related]
42. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
Hidaka K; Kimura T; Abdel-Rahman HM; Nguyen JT; McDaniel KF; Kohlbrenner WE; Molla A; Adachi M; Tamada T; Kuroki R; Katsuki N; Tanaka Y; Matsumoto H; Wang J; Hayashi Y; Kempf DJ; Kiso Y
J Med Chem; 2009 Dec; 52(23):7604-17. PubMed ID: 19954246
[TBL] [Abstract][Full Text] [Related]
43. Structural and kinetic analysis of pyrrolidine-based inhibitors of the drug-resistant Ile84Val mutant of HIV-1 protease.
Böttcher J; Blum A; Heine A; Diederich WE; Klebe G
J Mol Biol; 2008 Nov; 383(2):347-57. PubMed ID: 18692068
[TBL] [Abstract][Full Text] [Related]
44. HIV-1 protease mutations and inhibitor modifications monitored on a series of complexes. Structural basis for the effect of the A71V mutation on the active site.
Skalova T; Dohnalek J; Duskova J; Petrokova H; Hradílek M; Soucek M; Konvalinka J; Hasek J
J Med Chem; 2006 Sep; 49(19):5777-84. PubMed ID: 16970402
[TBL] [Abstract][Full Text] [Related]
45. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
46. The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease.
Coman RM; Robbins AH; Fernandez MA; Gilliland CT; Sochet AA; Goodenow MM; McKenna R; Dunn BM
Biochemistry; 2008 Jan; 47(2):731-43. PubMed ID: 18092815
[TBL] [Abstract][Full Text] [Related]
47. Characterization of a monoclonal antibody produced in an attempt to mimic the active site of HIV aspartyl protease using haptens based on inhibitor models.
Hanin V; Campagne JM; Dominice C; Mani JC; Dufour MN; Jouin P; Pau B
J Immunol Methods; 1994 Aug; 173(2):139-47. PubMed ID: 8046248
[TBL] [Abstract][Full Text] [Related]
48. A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions.
Seibold SA; Cukier RI
Proteins; 2007 Nov; 69(3):551-65. PubMed ID: 17623840
[TBL] [Abstract][Full Text] [Related]
49. Reactivity-based one-pot synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody.
Lee HK; Scanlan CN; Huang CY; Chang AY; Calarese DA; Dwek RA; Rudd PM; Burton DR; Wilson IA; Wong CH
Angew Chem Int Ed Engl; 2004 Feb; 43(8):1000-3. PubMed ID: 14966891
[No Abstract] [Full Text] [Related]
50. A phenylnorstatine inhibitor binding to HIV-1 protease: geometry, protonation, and subsite-pocket interactions analyzed at atomic resolution.
Brynda J; Rezacova P; Fabry M; Horejsi M; Stouracova R; Sedlacek J; Soucek M; Hradilek M; Lepsik M; Konvalinka J
J Med Chem; 2004 Apr; 47(8):2030-6. PubMed ID: 15056001
[TBL] [Abstract][Full Text] [Related]
51. Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution.
Ding J; Das K; Hsiou Y; Sarafianos SG; Clark AD; Jacobo-Molina A; Tantillo C; Hughes SH; Arnold E
J Mol Biol; 1998 Dec; 284(4):1095-111. PubMed ID: 9837729
[TBL] [Abstract][Full Text] [Related]
52. Monoclonal and polyclonal antibodies: reagents for studying HIV-1 proteinase variants.
Stoller TJ; Lim JJ; Woltizky BA; Graves MC
Adv Exp Med Biol; 1991; 306():507-10. PubMed ID: 1812750
[No Abstract] [Full Text] [Related]
53. Structure of a single-chain Fv fragment of an antibody that inhibits the HIV-1 and HIV-2 proteases.
Lescar J; Brynda J; Fabry M; Horejsi M; Rezacova P; Sedlacek J; Bentley GA
Acta Crystallogr D Biol Crystallogr; 2003 May; 59(Pt 5):955-7. PubMed ID: 12777823
[TBL] [Abstract][Full Text] [Related]
54. Crystal structure of PG16 antigen-binding portion reveals unusual features.
von Bubnoff A
IAVI Rep; 2010; 14(3):15-6. PubMed ID: 20666233
[No Abstract] [Full Text] [Related]
55. Conformational and dynamical basis for cross-reactivity observed between anti HIV-1 protease antibody with protease and an epitope peptide from it.
Badaya A; Sasidhar YU
Int J Biol Macromol; 2018 Oct; 118(Pt B):1696-1707. PubMed ID: 29990556
[TBL] [Abstract][Full Text] [Related]
56. Developing HIV-1 Protease Inhibitors through Stereospecific Reactions in Protein Crystals.
Olajuyigbe FM; Demitri N; De Zorzi R; Geremia S
Molecules; 2016 Oct; 21(11):. PubMed ID: 27809253
[TBL] [Abstract][Full Text] [Related]
57. X-ray structure of a tethered dimer for HIV-1 protease.
Bhat TN; Baldwin ET; Liu B; Cheng YS; Erickson JW
Adv Exp Med Biol; 1995; 362():439-44. PubMed ID: 8540354
[No Abstract] [Full Text] [Related]
58. Four distinct antigenic regions are present in the primary structure of HIV-1 and HIV-2 proteinases.
Björling E; Goobar-Larsson L; Utter G; Norrby E; Chiodi F
AIDS; 1992 Feb; 6(2):157-63. PubMed ID: 1373063
[TBL] [Abstract][Full Text] [Related]
59. [Immunoenzyme system for detection of antibodies in their complexes with HIV-1 antigens].
Abelian AV; Shchelkanov MIu; Burunova VV; Kabdulova DO; Karamov EV
Biull Eksp Biol Med; 1998 Aug; 126(8):189-92. PubMed ID: 9777234
[No Abstract] [Full Text] [Related]
60. New database.
Vondrasek J; Wlodawer A
Science; 1996 Apr; 272(5260):337-8. PubMed ID: 8602518
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
